Revision history of "IMTP-PNmAb.: Monoclonal antibody immunotherapy anti-bGAPDH" (Q2867043)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 March 2024

12 June 2023

23 May 2023

8 November 2022

29 July 2022

  • curprev 04:5504:55, 29 July 2022DG Regio talk contribs 39,602 bytes +23,765 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, da, ro, sv, nl, fr, de, it, pt, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, da, ro, sv,

20 January 2022

17 January 2022

18 December 2021

13 December 2021

4 December 2021

21 October 2021

13 September 2021

7 July 2021

  • curprev 19:1119:11, 7 July 2021DG Regio talk contribs 9,175 bytes +431 Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string
  • curprev 01:1101:11, 7 July 2021DG Regio talk contribs 8,744 bytes +117 Changed label, description and/or aliases in en: translated_label
  • curprev 01:1101:11, 7 July 2021DG Regio talk contribs 8,627 bytes +1,102 Created claim: summary (P836): PNmAb aims to create an innovative antibacterial antibacterial therapy directed against five of the bacteria most harmful to public health. This therapy is based on the discovery of a mechanism of virulence that is common to these bacteria and that results from years of research., translated_summary

6 July 2021

5 July 2021